Comparative Pharmacology
Head-to-head clinical analysis: HAILEY FE 1 5 30 versus NORLESTRIN 21 1 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HAILEY FE 1 5 30 versus NORLESTRIN 21 1 50.
HAILEY FE 1.5/30 vs NORLESTRIN 21 1/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive that suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Additionally, increases viscosity of cervical mucus and alters endometrial receptivity.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (LH, FSH). Enhances cervical mucus viscosity, reducing sperm penetration. Thins endometrium, decreasing implantation likelihood.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet (1 mg norethindrone acetate/50 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off therapy.
None Documented
None Documented
Ethinyl estradiol: terminal half-life ~17-24 hours; norethindrone: terminal half-life ~5-14 hours (mean 11 hours). The clinical significance is that steady-state is reached within 5-7 days.
Norethindrone terminal half-life: 5-14 hours; ethinyl estradiol terminal half-life: 10-20 hours. Clinical context: steady-state reached within 5-7 days, clinically significant for missed dose management.
Ethinyl estradiol is primarily excreted renally (40-45%) and via bile/feces (45-55%). Norethindrone is excreted 50-60% renally and 30-40% fecally.
Norethindrone: renal (33% as metabolites), fecal (50%); ethinyl estradiol: renal (40% as glucuronide conjugates), fecal (60%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive